Pub Date : 2026-01-01Epub Date: 2025-12-05DOI: 10.1016/j.ebiom.2025.106059
Xinying Cheng, Hao Cai, Xue Li, Yuxin Zhang, Siying Li, Yunkun Li, Na Hu, Su Lui, Jing Jing, Qiyong Gong, Kui Luo
Background: Chemotherapy remains the first-line treatment for triple-negative breast cancer (TNBC). Anthracycline chemotherapeutics, such as epirubicin (EPI), not only kill tumor cells but also induce immunogenic cell death (ICD). However, accumulated extracellular adenosine triphosphate (eATP) during ICD is converted to adenosine, triggering immunosuppression via adenosine receptor signalling. To address this issue, co-administration of EPI with adenosine receptor antagonists could remodel the immunosuppressive tumor microenvironment and potentiate antitumor immunity.
Methods: The effect of the expression level of adenosine receptors on the immune microenvironment of TNBC was assessed by integrating bioinformatic analysis of public databases with immunofluorescence staining of TNBC clinical samples. Four polymeric prodrugs of EPI were synthesised, and their delivery performances were assessed. A nanomedicine with pH/cathepsin B (CTSB)-responsiveness for co-delivery of EPI and AB928 (an adenosine receptor antagonist) was constructed. The cellular experiments and 4T1 tumor-bearing mice model were employed to evaluate antitumor efficacy.
Findings: Bioinformatic analyses and immunofluorescence staining of TNBC clinical samples supported the rationale for combining ICD-inducing chemotherapeutic agents with adenosine receptor antagonists. The polymeric prodrug of EPI with an optimal delivery efficiency was selected to encapsulate AB928. The constructed nanomedicine for EPI/AB928 co-delivery enhanced antitumor immune responses by effectively inhibiting adenosine-A2A receptor/A2B receptor (A2AR/A2BR) signalling pathways and reversing adenosine-mediated immunosuppression.
Interpretation: Co-delivery of an ICD inducer (EPI) and an adenosine receptor antagonist (AB928) is realised in a stimuli-responsive nanomedicine to address immunosuppression induced by adenosine, thereby enhancing ICD effects and synergistically reprogramming the immunosuppressive tumor microenvironment.
{"title":"Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines.","authors":"Xinying Cheng, Hao Cai, Xue Li, Yuxin Zhang, Siying Li, Yunkun Li, Na Hu, Su Lui, Jing Jing, Qiyong Gong, Kui Luo","doi":"10.1016/j.ebiom.2025.106059","DOIUrl":"10.1016/j.ebiom.2025.106059","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy remains the first-line treatment for triple-negative breast cancer (TNBC). Anthracycline chemotherapeutics, such as epirubicin (EPI), not only kill tumor cells but also induce immunogenic cell death (ICD). However, accumulated extracellular adenosine triphosphate (eATP) during ICD is converted to adenosine, triggering immunosuppression via adenosine receptor signalling. To address this issue, co-administration of EPI with adenosine receptor antagonists could remodel the immunosuppressive tumor microenvironment and potentiate antitumor immunity.</p><p><strong>Methods: </strong>The effect of the expression level of adenosine receptors on the immune microenvironment of TNBC was assessed by integrating bioinformatic analysis of public databases with immunofluorescence staining of TNBC clinical samples. Four polymeric prodrugs of EPI were synthesised, and their delivery performances were assessed. A nanomedicine with pH/cathepsin B (CTSB)-responsiveness for co-delivery of EPI and AB928 (an adenosine receptor antagonist) was constructed. The cellular experiments and 4T1 tumor-bearing mice model were employed to evaluate antitumor efficacy.</p><p><strong>Findings: </strong>Bioinformatic analyses and immunofluorescence staining of TNBC clinical samples supported the rationale for combining ICD-inducing chemotherapeutic agents with adenosine receptor antagonists. The polymeric prodrug of EPI with an optimal delivery efficiency was selected to encapsulate AB928. The constructed nanomedicine for EPI/AB928 co-delivery enhanced antitumor immune responses by effectively inhibiting adenosine-A2A receptor/A2B receptor (A2AR/A2BR) signalling pathways and reversing adenosine-mediated immunosuppression.</p><p><strong>Interpretation: </strong>Co-delivery of an ICD inducer (EPI) and an adenosine receptor antagonist (AB928) is realised in a stimuli-responsive nanomedicine to address immunosuppression induced by adenosine, thereby enhancing ICD effects and synergistically reprogramming the immunosuppressive tumor microenvironment.</p><p><strong>Funding: </strong>See Acknowledgements.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106059"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Climate change is increasing health risks worldwide, but how extreme temperature events affect Alzheimer's disease and other dementias (ADD) remains poorly understood. We aimed to project future extreme temperature event-attributable ADD deaths in China, accounting for the combined effects of climate change, population ageing, and adaptation methods.
Methods: We analysed 399,036 ADD deaths among adults aged ≥60 years in China during 2013-2020, using a time-stratified case-crossover design to estimate ADD mortality risks associated with extreme temperature events. We subsequently developed an integrated climate-ageing-adaptation framework that combined exposure-response functions, high-resolution climate projections, and demographic forecasts. Using this framework, we projected county-level ADD deaths attributable to heatwaves and cold spells among individuals aged ≥60 years across China under multiple SSP-RCP and adaptation scenarios for the 2030s, 2050s, and 2080s FINDINGS: Without adaptation, ADD heatwave-attributable deaths are projected to rise sharply, especially under rapid socioeconomic development with high greenhouse gas emissions scenario (SSP5-RCP8.5) in the 2080s, which reach 59,088-an 11-fold (+1003%) increase comparing to 2010s levels. Cold spell-attributable deaths generally decline but reductions are insufficient to offset the sharp rise in heatwave mortality, leading to a net increase in total attributable deaths. Adaptation strategies could avert up to 76.4% of heatwave-attributable deaths compared to no-adaptation scenario.
Interpretation: The convergence of climate change and population ageing is projected to substantially magnify dementia-related mortality in China. Under SSP5-RCP8.5, deaths attributable to extreme temperature events are projected to reach unprecedented levels by the end of the 21st century, especially without adaptation measures. These findings underscore the urgent need for massive greenhouse gases emission reductions alongside balanced, region-specific adaptation measures, and highlight dementia care as an essential component of climate resilience planning. Our study provides guidance for designing climate-resilient public health policies, particularly for ageing populations in climate-vulnerable counties and regions.
Funding: This work was supported by the Science and Technology Fundamental Resources Investigation Program of China [2017FY101201, 2017FY101206], and the National Foundation for Australia-China Relations of Australia [6016294].
{"title":"Projected extreme temperature event-attributable dementia deaths in China: a climate-ageing-adaptation framework.","authors":"Rui Zhang, Yonghong Li, Huan Zheng, Mulei Chen, Jia Zhao, Yiming Hu, Ainan Jia, Qing Guo, Songwang Wang, Liusen Wang, Ran Niu, Chaonan Wang, Qinmei Han, Xuejie Du, Lizhu Jin, Shaoqiong Li, Qiang Chen, Yujie Meng, Siyuan Wu, Bo Lu, Rong Zhao, Peng Bi, Jing Wu","doi":"10.1016/j.ebiom.2025.106072","DOIUrl":"10.1016/j.ebiom.2025.106072","url":null,"abstract":"<p><strong>Background: </strong>Climate change is increasing health risks worldwide, but how extreme temperature events affect Alzheimer's disease and other dementias (ADD) remains poorly understood. We aimed to project future extreme temperature event-attributable ADD deaths in China, accounting for the combined effects of climate change, population ageing, and adaptation methods.</p><p><strong>Methods: </strong>We analysed 399,036 ADD deaths among adults aged ≥60 years in China during 2013-2020, using a time-stratified case-crossover design to estimate ADD mortality risks associated with extreme temperature events. We subsequently developed an integrated climate-ageing-adaptation framework that combined exposure-response functions, high-resolution climate projections, and demographic forecasts. Using this framework, we projected county-level ADD deaths attributable to heatwaves and cold spells among individuals aged ≥60 years across China under multiple SSP-RCP and adaptation scenarios for the 2030s, 2050s, and 2080s FINDINGS: Without adaptation, ADD heatwave-attributable deaths are projected to rise sharply, especially under rapid socioeconomic development with high greenhouse gas emissions scenario (SSP5-RCP8.5) in the 2080s, which reach 59,088-an 11-fold (+1003%) increase comparing to 2010s levels. Cold spell-attributable deaths generally decline but reductions are insufficient to offset the sharp rise in heatwave mortality, leading to a net increase in total attributable deaths. Adaptation strategies could avert up to 76.4% of heatwave-attributable deaths compared to no-adaptation scenario.</p><p><strong>Interpretation: </strong>The convergence of climate change and population ageing is projected to substantially magnify dementia-related mortality in China. Under SSP5-RCP8.5, deaths attributable to extreme temperature events are projected to reach unprecedented levels by the end of the 21st century, especially without adaptation measures. These findings underscore the urgent need for massive greenhouse gases emission reductions alongside balanced, region-specific adaptation measures, and highlight dementia care as an essential component of climate resilience planning. Our study provides guidance for designing climate-resilient public health policies, particularly for ageing populations in climate-vulnerable counties and regions.</p><p><strong>Funding: </strong>This work was supported by the Science and Technology Fundamental Resources Investigation Program of China [2017FY101201, 2017FY101206], and the National Foundation for Australia-China Relations of Australia [6016294].</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106072"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12753258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-16DOI: 10.1016/j.ebiom.2025.106063
Athiththan Yogeswaran, Jeffrey S Annis, Meike Fünderich, Jochen Wilhelm, David G Kiely, Luke Howard, Allan Lawrie, Martin R Wilkins, Aparna Balasubramanian, Paul M Hassoun, Ziad Konswa, Christina A Eichstaedt, Ekkehard Grünig, Andrew J Sweatt, Roham T Zamanian, Gabor Kovacs, Horst Olschewski, Mona Lichtblau, Silvia Ulrich, Thenappan Thenappan, Imad Al Ghouleh, Stephen Y Chan, Jean Elwing, Arun Jose, John Cannon, Joanna Pepke-Zaba, Robert Frantz, Yuriy Sirenko, Olena Torbas, Sandeep Sahay, Zhenguo Zhai, Zhu Zhang, Alexandra Arvanitaki, George Giannakoulas, Marlize Frauendorf, Paul G Williams, Keiichiro Kuronuma, Hiromi Matsubara, Stefano Ghio, Laura Scelsi, Hanni Sabbour, Khaled Saleh, Anastasia Anthi, Effrosyni Dima, Raphael W Majeed, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Khodr Tello, Hector R Cajigas, Evan Brittain, Werner Seeger
Background: Sex-based differences in morbidity and mortality in pulmonary hypertension (PH) are underexplored, yet understanding these differences is vital for improving clinical management. This study investigates the influence of sex on survival of patients with PH in dependency of various disease conditions.
Methods: The PVRI GoDeep meta-registry integrates data from international PH registries, of which we analysed 21,123 incident hemodynamically fully characterised patients with PH. Survival analyses employed Kaplan-Meier and Cox proportional hazards models, adjusted for confounders and subjected to sensitivity analyses.
Findings: Male patients consistently showed significantly higher mortality than females across the overall PH population (hazard ratio 1.36 [1.23, 1.50] after adjustment) and within PAH and non-PAH groups. These sex differences in survival persisted regardless of P(A)H severities, age and obesity, cardiovascular diseases, and PAH-specific therapies. The male survival disadvantage was noted across low-, intermediate-, and high-risk groups of the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores, but not the REVEAL 2.0 risk score, which incorporates male sex as non-modifiable factor. Stratification by race revealed that male sex was associated with worse survival in White patients, but not in Black or Asian patients with PH.
Interpretation: Male patients with PH exhibit significantly higher mortality risks than females across both PAH and non-PAH PH groups. This disparity persists regardless of PH severity, underlying cause, age, obesity, comorbidities, or treatment status, though race might modify the observed risk difference. These insights provide new avenues for investigating underlying mechanisms and suggest including male sex as an independent factor in clinical risk assessment tools.
Funding: This work is funded by the Pulmonary Vascular Research Institute (PVRI) and the Cardiovascular Medical Research and Education Fund (CMREF), NIH.
背景:肺动脉高压(PH)发病率和死亡率的性别差异尚未得到充分研究,但了解这些差异对于改善临床管理至关重要。本研究探讨性别对PH依赖于各种疾病的患者生存的影响。方法:PVRI GoDeep meta-registry整合了来自国际PH登记处的数据,其中我们分析了21,123例血液动力学完全特征的PH患者。生存分析采用Kaplan-Meier和Cox比例风险模型,对混杂因素进行了调整,并进行了敏感性分析。研究结果:在整个PH人群中,以及在PAH和非PAH组中,男性患者的死亡率均明显高于女性(调整后的危险比为1.36[1.23,1.50])。无论P(A)H严重程度、年龄和肥胖、心血管疾病和pah特异性治疗,这些生存的性别差异都持续存在。在ESC/ERS 2022、REVEAL life 2和COMPERA 4层评分中,低、中、高风险组均存在男性生存劣势,但在将男性性别作为不可修改因素的REVEAL 2.0风险评分中没有。种族分层显示男性与白人PH患者的生存率较差相关,但与黑人或亚洲PH患者无关。解释:在PAH和非PAH PH组中,男性PH患者的死亡风险明显高于女性。尽管种族可能会改变观察到的风险差异,但无论PH严重程度、潜在原因、年龄、肥胖、合并症或治疗状态如何,这种差异都存在。这些见解为研究潜在机制提供了新的途径,并建议将男性性别作为临床风险评估工具的独立因素。资助:本研究由美国国立卫生研究院肺血管研究所(PVRI)和心血管医学研究与教育基金(CMREF)资助。
{"title":"Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment.","authors":"Athiththan Yogeswaran, Jeffrey S Annis, Meike Fünderich, Jochen Wilhelm, David G Kiely, Luke Howard, Allan Lawrie, Martin R Wilkins, Aparna Balasubramanian, Paul M Hassoun, Ziad Konswa, Christina A Eichstaedt, Ekkehard Grünig, Andrew J Sweatt, Roham T Zamanian, Gabor Kovacs, Horst Olschewski, Mona Lichtblau, Silvia Ulrich, Thenappan Thenappan, Imad Al Ghouleh, Stephen Y Chan, Jean Elwing, Arun Jose, John Cannon, Joanna Pepke-Zaba, Robert Frantz, Yuriy Sirenko, Olena Torbas, Sandeep Sahay, Zhenguo Zhai, Zhu Zhang, Alexandra Arvanitaki, George Giannakoulas, Marlize Frauendorf, Paul G Williams, Keiichiro Kuronuma, Hiromi Matsubara, Stefano Ghio, Laura Scelsi, Hanni Sabbour, Khaled Saleh, Anastasia Anthi, Effrosyni Dima, Raphael W Majeed, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Khodr Tello, Hector R Cajigas, Evan Brittain, Werner Seeger","doi":"10.1016/j.ebiom.2025.106063","DOIUrl":"10.1016/j.ebiom.2025.106063","url":null,"abstract":"<p><strong>Background: </strong>Sex-based differences in morbidity and mortality in pulmonary hypertension (PH) are underexplored, yet understanding these differences is vital for improving clinical management. This study investigates the influence of sex on survival of patients with PH in dependency of various disease conditions.</p><p><strong>Methods: </strong>The PVRI GoDeep meta-registry integrates data from international PH registries, of which we analysed 21,123 incident hemodynamically fully characterised patients with PH. Survival analyses employed Kaplan-Meier and Cox proportional hazards models, adjusted for confounders and subjected to sensitivity analyses.</p><p><strong>Findings: </strong>Male patients consistently showed significantly higher mortality than females across the overall PH population (hazard ratio 1.36 [1.23, 1.50] after adjustment) and within PAH and non-PAH groups. These sex differences in survival persisted regardless of P(A)H severities, age and obesity, cardiovascular diseases, and PAH-specific therapies. The male survival disadvantage was noted across low-, intermediate-, and high-risk groups of the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores, but not the REVEAL 2.0 risk score, which incorporates male sex as non-modifiable factor. Stratification by race revealed that male sex was associated with worse survival in White patients, but not in Black or Asian patients with PH.</p><p><strong>Interpretation: </strong>Male patients with PH exhibit significantly higher mortality risks than females across both PAH and non-PAH PH groups. This disparity persists regardless of PH severity, underlying cause, age, obesity, comorbidities, or treatment status, though race might modify the observed risk difference. These insights provide new avenues for investigating underlying mechanisms and suggest including male sex as an independent factor in clinical risk assessment tools.</p><p><strong>Funding: </strong>This work is funded by the Pulmonary Vascular Research Institute (PVRI) and the Cardiovascular Medical Research and Education Fund (CMREF), NIH.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106063"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-17DOI: 10.1016/j.ebiom.2025.106074
Shasha Li, Yan Liu, Haoshan Zhang, Simin Xu, Xiuzhen Wen, Yanhua Tang, Nana Zhang, David A Fox, Yanming Chen, Yunfeng Pan, Chenyang Lu
Background: Sjögren's Disease (SjD) is a systemic autoimmune disorder characterised by exocrine gland dysfunction and immune infiltration. However, the spatial cellular architecture and metabolic-immune crosstalk underlying glandular pathology in SjD remain unclear.
Methods: We performed spatial transcriptomics on SjD salivary glands (SGs) and conducted integrative analyses with single-cell RNA sequencing to delineate disease-specific transcriptomic alterations, followed by validation in an independent cohort. Key findings were verified via immunofluorescence, immunohistochemistry, and function assays on cells.
Findings: Spatial clustering revealed distinct perturbations in SjD. We identified a pathogenic CCL2high fibroblast-ACKR1high endothelial cell axis that co-localised in lymphoid foci and correlated with immune infiltration and disease activity. Chemokine-receptor axes were associated with immune infiltration, with endothelial ACKR1 facilitating inflammatory niche organisation. Compartmentalised immune-stroma niches exhibited upregulated phospholipid, glycerophospholipid and phosphatidylinositol metabolism in lymphoid foci, correlating with B/T-cell activation and interferon responses. Key metabolic regulators (PIK3CD, PIK3CG, PIKFYVE, and PLCG2) were elevated in SjD, associated with CD45+ cell abundance in SGs, and exhibited diagnostic potential. Conversely, epithelial cells showed suppressed glycerolipid metabolism and decreased MGLL expression, linked to enhanced antigen presentation. Inhibiting monoacylglycerol lipase (encoded by MGLL) upregulates MHC in A253 cells, while interferon-γ suppresses MGLL expression.
Interpretation: Our study elucidates spatially organised metabolic-immune networks in SjD, implicating lipid metabolism in immune activation and epithelial metabolic reprogramming in secretory dysfunction, nominating promising therapeutic targets.
Funding: National Natural Science Foundation of China (82104484,32301084), Joint funding from schools (colleges) and enterprises in Guangzhou (2025A03J3203, 2024A03J0987), Natural Science Foundation of Guangdong Province (2023A1515012790), Guangdong Provincial Enterprise Joint Fund (2022A1515220003), and Sun Yat-sen University (P02523).
{"title":"Spatial transcriptomics uncovers lipid metabolic dysregulation driving immune-stroma crosstalk in Sjögren's Disease.","authors":"Shasha Li, Yan Liu, Haoshan Zhang, Simin Xu, Xiuzhen Wen, Yanhua Tang, Nana Zhang, David A Fox, Yanming Chen, Yunfeng Pan, Chenyang Lu","doi":"10.1016/j.ebiom.2025.106074","DOIUrl":"10.1016/j.ebiom.2025.106074","url":null,"abstract":"<p><strong>Background: </strong>Sjögren's Disease (SjD) is a systemic autoimmune disorder characterised by exocrine gland dysfunction and immune infiltration. However, the spatial cellular architecture and metabolic-immune crosstalk underlying glandular pathology in SjD remain unclear.</p><p><strong>Methods: </strong>We performed spatial transcriptomics on SjD salivary glands (SGs) and conducted integrative analyses with single-cell RNA sequencing to delineate disease-specific transcriptomic alterations, followed by validation in an independent cohort. Key findings were verified via immunofluorescence, immunohistochemistry, and function assays on cells.</p><p><strong>Findings: </strong>Spatial clustering revealed distinct perturbations in SjD. We identified a pathogenic CCL2<sup>high</sup> fibroblast-ACKR1<sup>high</sup> endothelial cell axis that co-localised in lymphoid foci and correlated with immune infiltration and disease activity. Chemokine-receptor axes were associated with immune infiltration, with endothelial ACKR1 facilitating inflammatory niche organisation. Compartmentalised immune-stroma niches exhibited upregulated phospholipid, glycerophospholipid and phosphatidylinositol metabolism in lymphoid foci, correlating with B/T-cell activation and interferon responses. Key metabolic regulators (PIK3CD, PIK3CG, PIKFYVE, and PLCG2) were elevated in SjD, associated with CD45<sup>+</sup> cell abundance in SGs, and exhibited diagnostic potential. Conversely, epithelial cells showed suppressed glycerolipid metabolism and decreased MGLL expression, linked to enhanced antigen presentation. Inhibiting monoacylglycerol lipase (encoded by MGLL) upregulates MHC in A253 cells, while interferon-γ suppresses MGLL expression.</p><p><strong>Interpretation: </strong>Our study elucidates spatially organised metabolic-immune networks in SjD, implicating lipid metabolism in immune activation and epithelial metabolic reprogramming in secretory dysfunction, nominating promising therapeutic targets.</p><p><strong>Funding: </strong>National Natural Science Foundation of China (82104484,32301084), Joint funding from schools (colleges) and enterprises in Guangzhou (2025A03J3203, 2024A03J0987), Natural Science Foundation of Guangdong Province (2023A1515012790), Guangdong Provincial Enterprise Joint Fund (2022A1515220003), and Sun Yat-sen University (P02523).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106074"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-20DOI: 10.1016/j.ebiom.2025.106086
S Craig Roberts, Fabrice Damon, Karine Durand, Jan Havlíček, Dimitrios Kourtis, Ben Langford, Agnieszka Sorokowska, Piotr Sorokowski, Vivien Swanson, Jonathan Williams, Tatjana Arnoldi-Meadows, Dylan Brimaud, Daniela Dlouhá, Lucie Jelínková, Šárka Kaňková, Lenka Kapicová, Alice C Poirier, Kateřina Roberts, Justus C Sander, Dagmar Schwambergová, Michaela Silvestri, Nijing Wang, Emmanuel Simon, Benoist Schaal
Breastfeeding is crucial for infant survival, growth, and health, and it enhances maternal-infant bonding and well-being. However, breastfeeding rates typically fall below international targets, partly due to a high prevalence of latching difficulties, intermittent sucking, refusing the breast, or poor milk supply. Here, we propose that such uniquely human difficulties might be ameliorated by recognising, understanding, and facilitating the olfactory mechanisms that, in other mammals, regulate breastfeeding initiation and maternal-infant relationships in the first weeks of life. We briefly review evidence that odour mediates nipple-searching and suckling behaviour in other species, summarise the comparable evidence in humans, and outline pathways that could potentially reap hitherto unrealised benefits of olfactory communication between human mothers and neonates. We argue that enhanced awareness of such odour exchange could inform and enable changes in both policy and practice that might improve breastfeeding success and maternal-infant bonding, ultimately contributing to reduced infant mortality worldwide.
{"title":"Breastfeeding, bonding, and olfaction: unlocking the potential of mother-infant odour exchange.","authors":"S Craig Roberts, Fabrice Damon, Karine Durand, Jan Havlíček, Dimitrios Kourtis, Ben Langford, Agnieszka Sorokowska, Piotr Sorokowski, Vivien Swanson, Jonathan Williams, Tatjana Arnoldi-Meadows, Dylan Brimaud, Daniela Dlouhá, Lucie Jelínková, Šárka Kaňková, Lenka Kapicová, Alice C Poirier, Kateřina Roberts, Justus C Sander, Dagmar Schwambergová, Michaela Silvestri, Nijing Wang, Emmanuel Simon, Benoist Schaal","doi":"10.1016/j.ebiom.2025.106086","DOIUrl":"10.1016/j.ebiom.2025.106086","url":null,"abstract":"<p><p>Breastfeeding is crucial for infant survival, growth, and health, and it enhances maternal-infant bonding and well-being. However, breastfeeding rates typically fall below international targets, partly due to a high prevalence of latching difficulties, intermittent sucking, refusing the breast, or poor milk supply. Here, we propose that such uniquely human difficulties might be ameliorated by recognising, understanding, and facilitating the olfactory mechanisms that, in other mammals, regulate breastfeeding initiation and maternal-infant relationships in the first weeks of life. We briefly review evidence that odour mediates nipple-searching and suckling behaviour in other species, summarise the comparable evidence in humans, and outline pathways that could potentially reap hitherto unrealised benefits of olfactory communication between human mothers and neonates. We argue that enhanced awareness of such odour exchange could inform and enable changes in both policy and practice that might improve breastfeeding success and maternal-infant bonding, ultimately contributing to reduced infant mortality worldwide.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106086"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-23DOI: 10.1016/j.ebiom.2025.106089
Italo Fernandes, Jessica G Cockburn, Steven A Narod, Katarzyna J Jerzak
{"title":"Thyroid hormones and breast cancer: untangling the association.","authors":"Italo Fernandes, Jessica G Cockburn, Steven A Narod, Katarzyna J Jerzak","doi":"10.1016/j.ebiom.2025.106089","DOIUrl":"10.1016/j.ebiom.2025.106089","url":null,"abstract":"","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106089"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12800640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-24DOI: 10.1016/j.ebiom.2025.106095
Junghee J Shin, Hyeon Jun Shin, Alan Gutierrez, Noelle Yoo, Jennefer Par-Young, Lais Osmani, Min Sun Shin, Pedro A Sanchez-Lara, Richard Bucala, Gary Soffer, Insoo Kang
{"title":"Corrigendum: \"Decreased T helper 1 cell function underlies recurrent sinopulmonary infections in the 17q12 deletion syndrome\" EBioMedicine, 2025, Feb:112:105578.","authors":"Junghee J Shin, Hyeon Jun Shin, Alan Gutierrez, Noelle Yoo, Jennefer Par-Young, Lais Osmani, Min Sun Shin, Pedro A Sanchez-Lara, Richard Bucala, Gary Soffer, Insoo Kang","doi":"10.1016/j.ebiom.2025.106095","DOIUrl":"10.1016/j.ebiom.2025.106095","url":null,"abstract":"","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106095"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-05DOI: 10.1016/j.ebiom.2025.106055
Ajith Sivadasan, Paul Fernyhough, Nigel A Calcutt, Katie E Frizzi, Kimberly Gardner, Angela Hansen, Ari Breiner, Douglas W Zochodne, Natalia McInnes, Zubin Punthakee, Sylvie Gosselin, Bruce A Perkins, Vera Bril
<p><strong>Background: </strong>There is no effective definitive treatment for diabetic peripheral neuropathy (DPN). Strategies that target nerve pathology, limit nerve degeneration, and promote axon regeneration can potentially be beneficial. Topical pirenzepine promotes nerve fibre protection and repair in rodent models of type 1 and type 2 diabetes. We assessed the efficacy and safety of topical pirenzepine for the treatment of DPN.</p><p><strong>Methods: </strong>Preclinical studies were performed to determine efficacy of a topical formulation of 4% pirenzepine against indices of neuropathy in adult female Sprague-Dawley rats with streptozotocin (STZ)-induced diabetes. We then did a proof-of-concept randomised Phase 2a, double-blind, placebo-controlled, clinical trial conducted across 5 university centres in Canada. Participants (aged 18-75 years) with definite type-2 DPN, as defined by the Toronto Consensus Guidelines, who were on stable anti-diabetic and analgesic therapy prior to screening and during the study were enrolled. Participants were randomised to 1 of 4 treatment groups in a 1:1:4:4 ratio, where placebo (2 mL), placebo (4 mL); pirenzepine (2 mL of 4% formulation); and pirenzepine (4 mL of 4% formulation) were self-administered topically by the participants for a 24 weeks period. Safety and tolerability of 2 dose levels of 4% pirenzepine for 24 weeks was the primary objective. The primary efficacy endpoints were the change at 24 weeks from baseline in the intraepidermal nerve fibre density (IENFD) collected from the treated skin (ankle) and the impact on the Norfolk-quality of life-diabetic neuropathy (QOL-DN). Punch biopsies (3 mm) were collected and shipped to a centralised facility for processing and reading. The trial was approved by Health Canada (226063) and registered with ClinicalTrials.govNCT04005287.</p><p><strong>Findings: </strong>In rats, topically administered 4% pirenzepine (100 μl) to the hind paws applied 5 days per week for 6 weeks of diabetes prevented large fibre conduction slowing, touch-evoked allodynia, reduced mean axonal diameter, and small fibre mediated heat hypoalgesia and cold hyperalgesia. Two doses of topical pirenzepine or placebo were administered to 58 DPN individuals for 24 weeks, between October 15, 2019 and December 15, 2021. The least squares mean difference in change from baseline to week 24 in the IENFD at the ankle was 2.32 (p = 0.006) in the pirenzepine 4 mL group; 1.50 (p = 0.048) in the pirenzepine 2 mL group and -0.71 (p = 0.39) in placebo patients on the modified-intent-to-treat analysis (mITT). The change in IENFD at the ankle was significant in the combined pirenzepine groups compared to placebo (p = 0.012). No differences were observed in other parameters in the mITT population. There was a 10.4-point improvement in the Norfolk QOL-DN score in the combined treatment groups over placebo (p < 0.001) in the per protocol (PP) analysis set, but no difference was observed in the modified
{"title":"Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy.","authors":"Ajith Sivadasan, Paul Fernyhough, Nigel A Calcutt, Katie E Frizzi, Kimberly Gardner, Angela Hansen, Ari Breiner, Douglas W Zochodne, Natalia McInnes, Zubin Punthakee, Sylvie Gosselin, Bruce A Perkins, Vera Bril","doi":"10.1016/j.ebiom.2025.106055","DOIUrl":"10.1016/j.ebiom.2025.106055","url":null,"abstract":"<p><strong>Background: </strong>There is no effective definitive treatment for diabetic peripheral neuropathy (DPN). Strategies that target nerve pathology, limit nerve degeneration, and promote axon regeneration can potentially be beneficial. Topical pirenzepine promotes nerve fibre protection and repair in rodent models of type 1 and type 2 diabetes. We assessed the efficacy and safety of topical pirenzepine for the treatment of DPN.</p><p><strong>Methods: </strong>Preclinical studies were performed to determine efficacy of a topical formulation of 4% pirenzepine against indices of neuropathy in adult female Sprague-Dawley rats with streptozotocin (STZ)-induced diabetes. We then did a proof-of-concept randomised Phase 2a, double-blind, placebo-controlled, clinical trial conducted across 5 university centres in Canada. Participants (aged 18-75 years) with definite type-2 DPN, as defined by the Toronto Consensus Guidelines, who were on stable anti-diabetic and analgesic therapy prior to screening and during the study were enrolled. Participants were randomised to 1 of 4 treatment groups in a 1:1:4:4 ratio, where placebo (2 mL), placebo (4 mL); pirenzepine (2 mL of 4% formulation); and pirenzepine (4 mL of 4% formulation) were self-administered topically by the participants for a 24 weeks period. Safety and tolerability of 2 dose levels of 4% pirenzepine for 24 weeks was the primary objective. The primary efficacy endpoints were the change at 24 weeks from baseline in the intraepidermal nerve fibre density (IENFD) collected from the treated skin (ankle) and the impact on the Norfolk-quality of life-diabetic neuropathy (QOL-DN). Punch biopsies (3 mm) were collected and shipped to a centralised facility for processing and reading. The trial was approved by Health Canada (226063) and registered with ClinicalTrials.govNCT04005287.</p><p><strong>Findings: </strong>In rats, topically administered 4% pirenzepine (100 μl) to the hind paws applied 5 days per week for 6 weeks of diabetes prevented large fibre conduction slowing, touch-evoked allodynia, reduced mean axonal diameter, and small fibre mediated heat hypoalgesia and cold hyperalgesia. Two doses of topical pirenzepine or placebo were administered to 58 DPN individuals for 24 weeks, between October 15, 2019 and December 15, 2021. The least squares mean difference in change from baseline to week 24 in the IENFD at the ankle was 2.32 (p = 0.006) in the pirenzepine 4 mL group; 1.50 (p = 0.048) in the pirenzepine 2 mL group and -0.71 (p = 0.39) in placebo patients on the modified-intent-to-treat analysis (mITT). The change in IENFD at the ankle was significant in the combined pirenzepine groups compared to placebo (p = 0.012). No differences were observed in other parameters in the mITT population. There was a 10.4-point improvement in the Norfolk QOL-DN score in the combined treatment groups over placebo (p < 0.001) in the per protocol (PP) analysis set, but no difference was observed in the modified ","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106055"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2026-01-02DOI: 10.1016/j.ebiom.2025.106104
Mónica A Farías, Catalina A Andrade, Ricardo A Loaiza, Linmar Rodríguez-Guilarte, José T Muñoz, Patricia Pereira-Sánchez, Natalia Muñoz-Durango, Magdalena S Pizarro-Ortega, Benjamín Diethelm-Varela, Alejandra Pereira-Serrano, Robinson A Ramírez, José L Chávez, Karen Bohmwald, Jorge A Soto, Pablo A González, Susan M Bueno, Alexis M Kalergis
<p><strong>Background: </strong>The human respiratory syncytial virus (hRSV) is a pathogen of global concern, causing significant morbidity and mortality, mainly in preterm infants. To date, all licenced monoclonal antibodies (mAbs) developed against hRSV have targeted its surface fusion or pre-fusion protein (F-hRSV).</p><p><strong>Methods: </strong>We developed mAbs against the hRSV nucleoprotein (N-hRSV) as a complementary prophylactic treatment. Firstly, we produced a humanised murine mAb against N-hRSV, yielding four clones. Antibody affinity assays against the N-hRSV protein, pharmacokinetic analyses, and protection assays against pulmonary and neurological pathologies associated with hRSV infection in an in vivo male and female BALB/c murine model were performed. In vitro assays were carried out to determine the mechanisms of action of the humanised anti-N-hRSV mAbs, which exhibit antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</p><p><strong>Findings: </strong>Four humanised anti-N-hRSV mAb clones (P1-04H, P1-05D, P2-01A and P2-01D) were purified and showed high affinity for N-hRSV protein, as determined by SDS-PAGE and surface plasmon resonance, respectively. Pharmacokinetic analyses showed that two clones were detectable in the animals up to 30 days post-immunisation. Furthermore, treating mice with the humanised anti-N-hRSV mAb 1 day before hRSV infection reduced weight loss (P1-05D, ∗∗p = 0.0069; and P2-01D, p = 0.0875), clinical score (P1-05D, ∗∗p = 0.0052; P2-01A, ∗p = 0.04; P2-01D, ∗∗∗∗p < 0.0001), and pulmonary N-hRSV mRNA expression levels in hRSV serotype A-infected mice (P2-01A, p = 0.0612; P2-01D, p < 0.0613), while all animals infected with hRSV serotype B showed reduced levels of N-hRSV expression (P1-04H, ∗∗p = 0.0022; P1-05D, ∗∗p = 0.0013; P2-01A, ∗∗p = 0.0013; and P2-01D, ∗∗p = 0.0013). Brain viral load was also decreased (P1-04H; P1-05D; P2-01A; and P2-01D, ∗∗∗∗p < 0.0001). 30 days post-infection, behavioural tests indicated protection against long-term neurological alterations, with reduced faecal boli (P1-04H; and P2-01D, ∗p = 0.0243), altered centre preference (P1-04H; P1-05D; and P2-01D, ∗∗∗∗p < 0.0001), and restoration of marble burying behaviour (clone P2-01D, ∗∗p = 0.0055). Finally, in vitro analyses showed that the humanised anti-N-hRSV mAb displayed ADCC and CDC mechanisms to target infected cells.</p><p><strong>Interpretation: </strong>Our findings suggest that the humanised N-hRSV-specific mAbs displayed promising preclinical profiles by protecting against the pathology caused by hRSV infection.</p><p><strong>Funding: </strong>This study was supported by funding from the Millennium Institute on Immunology and Immunotherapy ANID ACE 210015 (CN09_016/ICN 2021_045; former P09/016-F, AMK); Biomedical Research Consortium CTU06 (AMK); FONDEF ID22I10252 (AMK and SMB); Fundación COPEC-UC 2019.R.1169 (AMK); FONDECYT Regular grant #1231866 (JAS), #1240971 (PAG), #1231905 (SMB)
{"title":"Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody.","authors":"Mónica A Farías, Catalina A Andrade, Ricardo A Loaiza, Linmar Rodríguez-Guilarte, José T Muñoz, Patricia Pereira-Sánchez, Natalia Muñoz-Durango, Magdalena S Pizarro-Ortega, Benjamín Diethelm-Varela, Alejandra Pereira-Serrano, Robinson A Ramírez, José L Chávez, Karen Bohmwald, Jorge A Soto, Pablo A González, Susan M Bueno, Alexis M Kalergis","doi":"10.1016/j.ebiom.2025.106104","DOIUrl":"10.1016/j.ebiom.2025.106104","url":null,"abstract":"<p><strong>Background: </strong>The human respiratory syncytial virus (hRSV) is a pathogen of global concern, causing significant morbidity and mortality, mainly in preterm infants. To date, all licenced monoclonal antibodies (mAbs) developed against hRSV have targeted its surface fusion or pre-fusion protein (F-hRSV).</p><p><strong>Methods: </strong>We developed mAbs against the hRSV nucleoprotein (N-hRSV) as a complementary prophylactic treatment. Firstly, we produced a humanised murine mAb against N-hRSV, yielding four clones. Antibody affinity assays against the N-hRSV protein, pharmacokinetic analyses, and protection assays against pulmonary and neurological pathologies associated with hRSV infection in an in vivo male and female BALB/c murine model were performed. In vitro assays were carried out to determine the mechanisms of action of the humanised anti-N-hRSV mAbs, which exhibit antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</p><p><strong>Findings: </strong>Four humanised anti-N-hRSV mAb clones (P1-04H, P1-05D, P2-01A and P2-01D) were purified and showed high affinity for N-hRSV protein, as determined by SDS-PAGE and surface plasmon resonance, respectively. Pharmacokinetic analyses showed that two clones were detectable in the animals up to 30 days post-immunisation. Furthermore, treating mice with the humanised anti-N-hRSV mAb 1 day before hRSV infection reduced weight loss (P1-05D, ∗∗p = 0.0069; and P2-01D, p = 0.0875), clinical score (P1-05D, ∗∗p = 0.0052; P2-01A, ∗p = 0.04; P2-01D, ∗∗∗∗p < 0.0001), and pulmonary N-hRSV mRNA expression levels in hRSV serotype A-infected mice (P2-01A, p = 0.0612; P2-01D, p < 0.0613), while all animals infected with hRSV serotype B showed reduced levels of N-hRSV expression (P1-04H, ∗∗p = 0.0022; P1-05D, ∗∗p = 0.0013; P2-01A, ∗∗p = 0.0013; and P2-01D, ∗∗p = 0.0013). Brain viral load was also decreased (P1-04H; P1-05D; P2-01A; and P2-01D, ∗∗∗∗p < 0.0001). 30 days post-infection, behavioural tests indicated protection against long-term neurological alterations, with reduced faecal boli (P1-04H; and P2-01D, ∗p = 0.0243), altered centre preference (P1-04H; P1-05D; and P2-01D, ∗∗∗∗p < 0.0001), and restoration of marble burying behaviour (clone P2-01D, ∗∗p = 0.0055). Finally, in vitro analyses showed that the humanised anti-N-hRSV mAb displayed ADCC and CDC mechanisms to target infected cells.</p><p><strong>Interpretation: </strong>Our findings suggest that the humanised N-hRSV-specific mAbs displayed promising preclinical profiles by protecting against the pathology caused by hRSV infection.</p><p><strong>Funding: </strong>This study was supported by funding from the Millennium Institute on Immunology and Immunotherapy ANID ACE 210015 (CN09_016/ICN 2021_045; former P09/016-F, AMK); Biomedical Research Consortium CTU06 (AMK); FONDEF ID22I10252 (AMK and SMB); Fundación COPEC-UC 2019.R.1169 (AMK); FONDECYT Regular grant #1231866 (JAS), #1240971 (PAG), #1231905 (SMB)","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106104"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12805088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}